All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, February 5, 2023
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Financings for Sept. 13, 2022

Sep. 13, 2022
No Comments
Biopharmas in Asia-Pacific raising money in public or private financings: Kuria, Neukio.
Read More
Brain scan illustration

Pharmaxis finds new hope for PXS-4728 in neurodegenerative diseases

Sep. 13, 2022
By Tamra Sami
No Comments
Pharmaxis Ltd. has found new funding to breathe life into a drug that looked like it might sit on the shelf for a while, but now appears to be a good candidate for tackling Parkinson’s and other neurodegenerative diseases.
Read More

Rapid ‘Rayze’: Rayzebio closes $160M series D round, targets lead asset at Lutathera failures

Sep. 13, 2022
By Cormac Sheridan
No Comments
Rayzebio Inc. raised $160 million in a series D round and unveiled its lead targeted radiopharmaceutical drug candidate, RYZ-101, which has entered clinical development in patients with gastroenteropancreatic neuroendocrine tumors expressing the somatostatin receptor type 2.
Read More
Australian coins and bills

Occurx raises AU$16M to progress lead candidate OCX-063 in chronic kidney disease as it looks for partners

Sep. 13, 2022
By Tamra Sami
No Comments
Melbourne-based Occurx Pty Ltd. announced a AU$16 million (US$11 million) series B round that will progress lead candidate OCX-063 to phase II trials in chronic kidney disease. The capital raise was jointly led by Brandon Biocatalyst and Uniseed and includes a AU$1.5 million grant from Australian biomedical incubator Cureator.
Read More

Junshi to raise $570M for drug development, headquarter building

Sep. 13, 2022
By Doris Yu
No Comments
Shanghai Junshi Biosciences Co. Ltd. plans to raise up to ¥3.969 billion (US$570 million) by issuing no more than 70 million A shares to target subscribers on the Shanghai STAR Market.
Read More

Financings for Sept. 13, 2022

Sep. 13, 2022
No Comments
Biopharmas raising money in public or private financings, including: Acelyrin, Alnylam, Casinvent, Codiak, Edgewise, Forge, Relay, Revance, Satellos, Vitro.
Read More
Mitochondria illustration
Genetic/congenital

Pretzel Therapeutics launches with focus on mitochondrial biology

Sep. 13, 2022
No Comments
Pretzel Therapeutics Inc. has launched with a $72.5 million series A financing to pioneer novel therapies to modulate mitochondrial function to treat rare genetic diseases and common diseases of aging.
Read More

Financings for Sept. 12, 2022

Sep. 12, 2022
No Comments
Med-tech firms raising money in public or private financings, including: Adaptive Biotechnologies, Phantom Neuro, Verily Life Sciences.
Read More

Financings for Sept. 12, 2022

Sep. 12, 2022
No Comments
Biopharmas raising money in public or private financings, including: Adaptive, Alnylam, Anacardio, Alopexx, Aqilion, Arpeggio, Arsenal, BMS, Basilea, Cour, Iliad, Inmed, Nimbus, Pretzel, Qli5, Relay, Reviva, Shuttle, Third Harmonic, Tscan.
Read More

Financings for Sept. 9, 2022

Sep. 9, 2022
No Comments
Med-tech firms raising money in public or private financings, including: Innervace.
Read More
Previous 1 2 … 33 34 35 36 37 38 39 40 41 … 360 361 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 3, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Feb. 3, 2022.
  • Setpoint Medical - vagus nerve stimulation device

    Setpoint Medical lands up to $145M to advance RA implant

    BioWorld MedTech
    Bioelectronic medicine startup Setpoint Medical Corp. raised $80 million in a preferred stock financing co-led by new investors Norwest Venture Partners and...
  • CFIUS singles out mergers with Chinese companies as potential national security threats

    BioWorld
    Proposed mergers with Chinese companies will likely be subject to increased scrutiny from the Committee on Foreign Investment in the United States (CFIUS) as...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing